Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 276 participants.
Also called NCT01365507
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 276 participants
- Sponsor
- Registry
-
NCT01365507
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Malaysia, Mexico, Puerto Rico, South Korea, Thailand, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT01365507. Randomized; no masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2012-04 (actual). Results posted on 2015-11-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens
- Acronym
- BOOST™
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec/insulin aspart
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01365507- Content hash
14972541cfcece8166de581b381c939739868c5130ad666161f38a2f56a22f55